Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karaçin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Celebi, Abdussamet; Yılmaz, Hatice; Kuzu, Omer F.; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzafer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Sakalar, Teoman; Öktem, İlker Nihat; Eren, Tulay; Erul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet; Şahin, Elif; Seyyar, Mustafa; Özdemır, Özlem; Selçukbiricik, Fatih; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; Imamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kivrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan

doi:10.1186/s12885-023-10662-3

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multicenter, retrospective study, no differences in PFS between endocrine therapy and chemotherapy following progression under CDK4/6i were observed ( 17 ). After progression under CDK4/6i in the first line, the median PFS for chemotherapy was 5.3 months and 9.5 months for endocrine treatment, whereas it was 5.7 months and 6.7 months, respectively, after progression under CDK4/6i in the second line ( 17 ). Similarly, our study did not find significant differences between these two modalities, with a median PFS of 4.3 months for chemotherapy-only and 5.7 months for endocrine-based treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

Kubeczko,

Polakiewicz-Gilowska,

Świderska

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represent the gold standard of the hormone receptor positive human epidermal growth factor receptor 2 (HER-2) negative advanced breast cancer. However, optimal treatment after disease progression is a matter of debate. We aimed to assess predictive and prognostic factors associated with the treatment outcome following CDK4/6i progression.MethodsWe retrospectively analyzed patients who progressed on CDK4/6i treatment between 2018 and 2024. Treatment based on molecular findings (PIK3CA mutation), genetic findings (BRCA1/2 germline mutation), or adapted to the change in the tumor phenotype in rebiopsy (anti-HER2 therapy in the transformation to HER-2-positive disease) was grouped into tailored treatment and compared to the endocrine-based therapy and chemotherapy alone.ResultsFive hundred twelve patients were treated with CDK4/6i. Two hundred patients with disease progression were enrolled in the study. Duration of response to CDK4/6i was not predictive of the response to subsequent treatment, whereas the progression in the central nervous system was the worst prognostic factor. Thirty patients were ineligible for subsequent treatment. Survival after CDK4/6i progression was significantly longer in patients eligible for tailored treatment. The median PFS in patients with tailored treatment (n=19) was 13.5 months vs. 4.9 months in patients with non-tailored therapy (n=151; p=0.045). 12-month PFS was 54.1% with tailored treatment [95% CI 24.1–76.7%] compared to 18.5% with non-tailored therapy [95% CI 11.6–26.6%]. The median OS for patients treated with a tailored approach was not reached compared to 11.5 months with non-tailored treatment (p=0.016). The 24-month OS for patients treated with a tailored approach was 80.2% [95% CI 40.3–94.8%] compared to 21.1% [95% CI 12.2–31.7%] for patients with non-tailored treatment.ConclusionsTailoring of subsequent treatment strategy seems to be essential for achieving long-term benefit. Further studies are required, as the prognosis after CDK4/6i progression remains dismal, especially in cases affecting the central nervous system.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Studies regarding the management of patients experiencing disease progression under CDK4/6i often focus only on patients receiving subsequent treatment ( 17 , 19 , 20 ). However, a significant number of patients do not receive any subsequent therapy after CDK4/6i discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

Kubeczko,

Polakiewicz-Gilowska,

Świderska

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

New Eco-Friendly, Biocompatible, Bactericidal, Fungicidal and Anticancer-Activity-Exhibiting Nanocomposites Based on Bimetallic TiO2@Cr2O3 Nanoparticle Core and Biopolymer Shells

Hasanin,

Elhenawy,

Abdel-Hamid

et al. 2023

J. Compos. Sci.

View full text Add to dashboard Cite

Nanoparticles have attracted substantial attention for their diverse range of applications, particularly in biomedicine applications and drug delivery, owing to their unique properties. However, their tiny size facilitates easy cellular entry, which can also lead to interactions with cellular components, potentially resulting in toxicity and undesirable effects. In this study, a novel nanocomposite formulation was developed using biopolymers, specifically ethylcellulose and collagen, as capping and stabilizing agents to create bimetallic nanoparticles including TiO2@Cr2O3 nanoparticles. Physicochemical and morphological analyses were carried out to validate the formulation’s structure. The obtained characteristics emphasized the presence of a nanostructure involving bimetallic nanoparticles. This formulation exhibited excellent biological activity, including high biocompatibility with Vero and WI38 cells at concentrations of 40.4 and 52 µg/mL, respectively, as well as effective anticancer activity with significant selectivity. The IC50 values were determined to be 19 and 22 µg/mL for MCF7 and A549 cells, respectively. The antimicrobial assessment revealed the highest MIC value for A. niger at 50 µg/mL, while the lowest MIC value was observed for Gram-positive bacteria at 3.12 µg/mL. Additionally, the nanocomposite demonstrated antioxidant activity at a low concentration of 1.5 µg/mL.

show abstract

Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cited by 2 publications

References 1 publication

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis

New Eco-Friendly, Biocompatible, Bactericidal, Fungicidal and Anticancer-Activity-Exhibiting Nanocomposites Based on Bimetallic TiO2@Cr2O3 Nanoparticle Core and Biopolymer Shells

Contact Info

Product

Resources

About